How Shared Clinical Decision-Making Is Changing Pediatric Vaccine Conversations—And What Manufacturers Must Do

The routine vaccine visit is no longer routine.

The CDC's recent update to the childhood immunization schedule has shifted the framework for several key vaccines—including Flu, COVID-19, Meningococcal, and Hepatitis A—toward Shared Clinical Decision-Making (SCDM). For manufacturers with products in these categories, the implications are significant: guaranteed uptake no longer exists, and the burden of driving voluntary vaccination now falls on a combination of HCP advocacy and caregiver readiness.

ZoomRx fielded a dual-audience study in January–February 2026—surveying 50 US pediatric HCPs and 50 caregivers—to capture the early operational reality of this shift.

What the Data Reveals

 First, HCPs and caregivers are not on the same page. 68% of caregivers interpret SCDM as reassurance that recommendations are individualized to their child. Meanwhile, 48% of HCPs worry it signals that the vaccine is optional—a perception they see creating friction in their clinics. 

 Furthermore, vaccine conversations are getting longer and harder. 70% of HCPs expect to spend more time explaining disease severity and risk in children. 52% expect more time addressing vaccine safety concerns driven by misinformation on platforms like TikTok or Facebook. HCPs cite adding an average of 2–3 minutes per visit for these discussions—time they report they simply do not have. 

 The study also revealed that vaccine acceptance follows a clear hierarchy. Mandated vaccines remain routine. However, Flu and COVID-19 now face the greatest resistance, requiring disproportionate HCP time to address refusal barriers rather than just simple hesitancy. 

 Finally, caregivers want individualized guidance—but aren't always getting it. The data shows that explaining how well a vaccine works for their specific children is a key driver of caregiver decision comfort (A1), yet HCPs consistently underestimate this impact, viewing it as an "underleveraged opportunity". 

Three Things Manufacturers Can Do Now

1. Simplify the science. Visual aids and leave-behinds that translate complex data into relatable narratives increase caregiver buy-in and reduce the time HCPs spend justifying recommendations from scratch.
2. Equip HCPs with conversation probes. Ready-to-use dialogue tools that help caregivers open up—without extending visit time—allow HCPs to personalize discussions efficiently.
3. Educate caregivers before the visit. Manufacturers who invest in upstream caregiver education ensure that patients arrive informed, reducing clinic friction and supporting higher voluntary uptake.
   
   

You’ll get direct access to:

• Dual-audience findings across 50 HCPs and 50 caregivers

• The acceptance hierarchy across mandated vs SCDM vaccines

• HCP verbatims on misinformation burden and time constraints

• HCP versus caregiver perception gap – and how to bridge it

For a more granular view, you can explore these findings via ZoomRx Answers. Ask natural language questions to generate custom data views, listen to direct HCP voice clips, and review research artifacts in real-time.